Figure 7.

Inhibiting HMGA1 leads to reduced sensitivity of ESCC to rapamycin in vivo. (A) A syngeneic subcutaneous ESCC model in mice. AKR mouse esophageal cancer cells with HMGA1 silenced or unsilenced were injected subcutaneously into the axilla of C57BL/6 mice, followed by intraperitoneal injection of rapamycin (2 mg/kg) after one week, with an additional injection every 48 hours. (B) Subcutaneous tumor weight and volume in syngeneic mice at endpoint were calculated for each group of mice (n = 4) using the formula (length × width²) × 0.52 and presented as mean ± SEM. (C) IHC staining of HMGA1, p-S6, and FKBP12 in the syngeneic tumor tissues (slice = 4 μm). Representative IHC staining images were presented, scale = 50 μm (left) and 100 μm (right).